Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea.

Millar RP, Sonigo C, Anderson RA, George J, Maione L, Brailly-Tabard S, Chanson P, Binart N, Young J

Journal of the Endocrine Society16 Oct 2017Cited by 50 (Europe PMC)

PMID29264460PMCIDPMC5686678DOI10.1210/js.2017-00328PepBankPUB-29264460

Summary

ContextHyperprolactinemia-induced hypogonadotropic amenorrhea (hPRL-HA) is a major cause of hypothalamic gonadotrophin-releasing hormone (GnRH) deficiency in women. In hyperprolactinemic mice, we previously demonstrated that hypothalamic kisspeptin (Kp) expression was diminished and that Kp administration restored hypothalamic GnRH release, gonadotropin secretion, and ovarian cyclicity, suggesting that Kp neurons could also play a role in hPRL-HA.ObjectiveTo study the effect of Kp-10 on the gonadotropic-ovarian axis in women with hPRL-HA.PatientsTwo women (32 and 36 years old) with chronic hPRL-HA (prolactin: between 94 and 102 and 98 and 112 ng/mL, respectively) caused by cabergoline-resistant microprolactinomas.InterventionsCabergoline was discontinued 6 months before inclusion. Blood samples were taken every 10 minutes for 12 hours during 2 consecutive days to evaluate luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. Serum estradiol (E2), testosterone (T), and inhibin B (IB) levels were also measured. Vehicle or Kp-10 (1.5 μg/kg/h) was infused intravenously for 12 hours.ResultsKp-10 induced a significant increase in LH and FSH levels and increased LH pulses. E2, T, and IB serum levels were also significantly increased.ConclusionsIn this exploratory study, we demonstrated that administration of Kp-10 reactivated gonadotropin secretion in women with hPRL-HA and increased ovarian activity. Our data suggest that, as in rodents, GnRH deficiency in hPRL-HA is also mediated by an impairment of hypothalamic Kp secretion. Kp-10 or its analogues could have therapeutic application as an alternative approach to restore ovarian function and fertility in women with hPRL-HA resistant to dopamine agonists and in whom pituitary surgery is not possible.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanCase report or seriesEfficacy outcome
In two women with hyperprolactinemic amenorrhea, an intravenous infusion of kisspeptin‑10 increased luteinizing hormone levels versus vehicle.
In plain wordsIn two women with hyperprolactinemic amenorrhea, kisspeptin‑10 raised luteinizing hormone levels compared with vehicle.
Peptide
Kisspeptin-10
Outcome
IncreaseLH levels
Study
n = 2
Comparator
Vehicle
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.5 μg/kg/h · intravenous · 12 hoursAs given in this study (human).
Source sentences
Summary
Kp-10 induced a significant increase in LH and FSH levels
1 context sentence(design, population, supporting numbers)
Summary · context
Two women (32 and 36 years old) with chronic hPRL-HA (prolactin: between 94 and 102 and 98 and 112 ng/mL, respectively) caused by cabergoline-resistant microprolactinomas.
Show in the study text Report a problemFND-2926446001
02HumanCase report or seriesEfficacy outcome
In two women with hyperprolactinemic amenorrhea, an intravenous infusion of kisspeptin‑10 increased follicle-stimulating hormone levels versus vehicle.
In plain wordsIn two women with hyperprolactinemic amenorrhea, kisspeptin‑10 raised follicle-stimulating hormone levels compared with vehicle.
Peptide
Kisspeptin-10
Outcome
IncreaseFSH levels
Study
n = 2
Comparator
Vehicle
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.5 μg/kg/h · intravenous · 12 hoursAs given in this study (human).
Source sentences
Summary
Kp-10 induced a significant increase in LH and FSH levels
1 context sentence(design, population, supporting numbers)
Summary · context
Two women (32 and 36 years old) with chronic hPRL-HA (prolactin: between 94 and 102 and 98 and 112 ng/mL, respectively) caused by cabergoline-resistant microprolactinomas.
Show in the study text Report a problemFND-2926446002
03HumanCase report or seriesEfficacy outcome
In two women with hyperprolactinemic amenorrhea, kisspeptin‑10 infusion increased the number of luteinizing hormone pulses versus vehicle.
In plain wordsIn two women with hyperprolactinemic amenorrhea, kisspeptin‑10 increased luteinizing hormone pulses compared with vehicle.
Peptide
Kisspeptin-10
Outcome
IncreaseLH pulses
Study
n = 2
Comparator
Vehicle
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.5 μg/kg/h · intravenous · 12 hoursAs given in this study (human).
Source sentences
Summary
increased LH pulses.
1 context sentence(design, population, supporting numbers)
Summary · context
Two women (32 and 36 years old) with chronic hPRL-HA (prolactin: between 94 and 102 and 98 and 112 ng/mL, respectively) caused by cabergoline-resistant microprolactinomas.
Show in the study text Report a problemFND-2926446003
04HumanCase report or seriesEfficacy outcome
In two women with hyperprolactinemic amenorrhea, kisspeptin‑10 infusion significantly increased serum estradiol versus vehicle.
In plain wordsIn two women with hyperprolactinemic amenorrhea, kisspeptin‑10 raised estradiol levels compared with vehicle.
Peptide
Kisspeptin-10
Outcome
IncreaseSerum estradiol
Study
n = 2
Comparator
Vehicle
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.5 μg/kg/h · intravenous · 12 hoursAs given in this study (human).
Source sentences
Summary
E2, T, and IB serum levels were also significantly increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Two women (32 and 36 years old) with chronic hPRL-HA (prolactin: between 94 and 102 and 98 and 112 ng/mL, respectively) caused by cabergoline-resistant microprolactinomas.
Show in the study text Report a problemFND-2926446004
05HumanCase report or seriesEfficacy outcome
In two women with hyperprolactinemic amenorrhea, kisspeptin‑10 infusion significantly increased serum testosterone versus vehicle.
In plain wordsIn two women with hyperprolactinemic amenorrhea, kisspeptin‑10 raised testosterone levels compared with vehicle.
Peptide
Kisspeptin-10
Outcome
IncreaseSerum testosterone
Study
n = 2
Comparator
Vehicle
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.5 μg/kg/h · intravenous · 12 hoursAs given in this study (human).
Source sentences
Summary
E2, T, and IB serum levels were also significantly increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Two women (32 and 36 years old) with chronic hPRL-HA (prolactin: between 94 and 102 and 98 and 112 ng/mL, respectively) caused by cabergoline-resistant microprolactinomas.
Show in the study text Report a problemFND-2926446005
06HumanCase report or seriesEfficacy outcome
In two women with hyperprolactinemic amenorrhea, kisspeptin‑10 infusion significantly increased serum inhibin B versus vehicle.
In plain wordsIn two women with hyperprolactinemic amenorrhea, kisspeptin‑10 raised inhibin B levels compared with vehicle.
Peptide
Kisspeptin-10
Outcome
IncreaseSerum inhibin B
Study
n = 2
Comparator
Vehicle
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1.5 μg/kg/h · intravenous · 12 hoursAs given in this study (human).
Source sentences
Summary
E2, T, and IB serum levels were also significantly increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Two women (32 and 36 years old) with chronic hPRL-HA (prolactin: between 94 and 102 and 98 and 112 ng/mL, respectively) caused by cabergoline-resistant microprolactinomas.
Show in the study text Report a problemFND-2926446006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.